Skip to main content

Table 2 Course of sleep quality throughout the study

From: Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study

Patients

Baseline visit

6-month visit

12-month visit

18-month visit

24-month visit

All patients, N

128

109

96

65

61

Patients with evaluable questionnaires, N

106

90

82

51

41

PSQI mean (SD)

7.31 (4.36)

6.37 (3.99)

6.43 (4.03)

6.45 (4.48)

6.71 (4.11)

PSQI median (range)

6.0 (1.0–18.0)

5.5 (1.0–20.0)

5.0 (1.0–18.0)

5.0 (0.0–18.0)

5.0 (1.0–18.0)

Proportion of patients with PSQI≥5 (95% confidence interval)

55.47 (46.43–64.25)

46.79 (37.17–56.59)

50.00 (39.62–60.38)

49.23 (36.60–61.93)

37.70 (25.61–51.04)

Sensitivity analysis, N

28

28

28

28

28

PSQI mean (SD)

6.75 (3.95)

6.43 (4.26)

6.00 (3.22)

6.21 (4.07)

6.29 (3.61)

PSQI median (range)

5.0 (1.0–14.0)

4.0 (1.0–18.0)

5.5 (2.0–14.0)

5.0 (1.0–18.0)

5.0 (1.0–16.0)

Proportion of patients with PSQI≥5 (95% confidence interval)

57.14 (37.18–75.54)

46.43 (27.51–66.13)

57.14 (37.18–75.54)

64.29 (44.07–81.36)

53.57 (33.87–72.49)

  1. PSQI Pittsburgh Sleep Quality Index, SD standard deviation